The NPM1 mutation type has no impact on survival in cytogenetically normal AML 
B) NPM1 mutation types A versus B versus D versus other mutations in 292 patients receiving chemotherapy only
The NPM1 mutation types NPM1-A versus NPM1-B versus NPM1-D versus NPM1-others did not reveal significant differences with regard to OS and RFS, neither in all patients (p=0.936 p=0.970, respectively), nor in patients with or without an additional FLT3-ITD (data not shown). Multivariable Cox regression revealed the same risk factors for an adverse OS and RFS as for all patients. Mutations K m to Q m refer to mutations identified by Schnittger et al. 4 Mutation 13 refers to the mutations identified by Döhner et al. 5 Mutations M* to Y* refer to newly identified mutations identified by our group.
Abbreviations: Wt, wild-type 
